by guojie | Jan 25, 2022 | Uncategorized
According to MyBio data statistics, totally 281 BD licensing deals occurred in 2021 in China pharmaceutical industry. 1. The 281 deals include 174 cross-border licenses and 107 licenses between Chinese bios. 2. The 174 cross-border licenses include 133 License-in... by guojie | Apr 1, 2021 | Uncategorized
MyBio Capital partner Dr. Ginger Ding hosted a fire chat session at China Focus Global Life Science Summit. Joining together are Jonathan Wang, CEO of Inmagene Biopharmaceuticals, Jimmy Zhang, CEO of AccuGen Group, John Zhu, Venture partner of 6 Dimensions... by guojie | Feb 27, 2021 | Uncategorized
Under the dual driving forces of regulatory changes and capital pouring into the industry, China’s life sciences sector has become active in cross-border collaboration (licensing, investments, M&A) and achieved explosive growth in 2020. In 2021, MyBio... by guojie | Jan 31, 2021 | Uncategorized
Under the dual driving forces of regulatory changes and capital pouring into the industry, China’s life sciences sector has become active in cross-border collaboration (licensing, investments, M&A) and achieved explosive growth in 2020. In 2021, MyBio...